Literature DB >> 6511129

Influence of dose in the urinary excretion of amikacin.

J M Lanao, J L Pedraz, A S Navarro, A Dominguez-Gil.   

Abstract

The urinary excretion kinetics of amikacin was studied in 28 healthy volunteers who received doses of 125, 250 and 500 mg of the antibiotic. The average percentages of the dose excreted were 67.67, 79.4 and 68.65% for each dose, respectively. The elimination constant (Ke), the urinary excretion constant (Ku) and the extra-renal excretion constant (Knr) had similar values for the three groups studied. The average value obtained for Knr showed the existence of a moderate extra-renal excretion of amikacin. A linear relationship was observed between the maximum excretion rate (Vmax) and the dose administered (D), according to the equation: Vmax (mg/h) = 3.714 + 0.207 X D (mg); r = 1.000 This relationship reveals the linear kinetics of renal excretion in the dose range studied. In view of the high urinary concentrations obtained, it is concluded that amikacin doses of 4 mg/kg/day should ensure therapeutic urinary concentrations sufficient to combat most amikacin-susceptible organisms.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6511129

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  2 in total

1.  Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.

Authors:  Michael J Satlin; Christine J Kubin; Jill S Blumenthal; Andrew B Cohen; E Yoko Furuya; Stephen J Wilson; Stephen G Jenkins; David P Calfee
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 2.  Cystatin C as a potential biomarker for dosing of renally excreted drugs.

Authors:  Nguessan Aimé Brou; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.